Document Detail


Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study.
MedLine Citation:
PMID:  21115547     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND AND AIMS: Few studies have been conducted addressing the safety of thiopurine treatment in pregnant women with inflammatory bowel disease (IBD). The aim of this study was to evaluate the pregnancy outcome of women with IBD who have been exposed to thiopurines.
METHODS: 215 pregnancies in 204 women were registered and documented in the CESAME cohort between May 2004 and October 2007. Physicians documented the following information from the women: last menstrual date, delivery term, details of pregnancy outcome, prematurity, birth weight and height, congenital abnormalities, medication history during each trimester, smoking history and alcohol ingestion. Data were compared between three groups: women exposed to thiopurines (group A), women receiving a drug other than thiopurines (group B) and women not receiving any medication (group C).
RESULTS: Mean age at pregnancy was 28.3 years. 75.7% of the women had Crohn's disease and 21.8% had ulcerative colitis, with a mean disease duration of 6.8 years at inclusion. Of the 215 pregnancies, there were 138 births (142 newborns), and the mean birth weight was 3135 g. There were 86 pregnancies in group A, 84 in group B and 45 in group C. Interrupted pregnancies occurred in 36% of patients enrolled in group A, 33% of patients enrolled in group B, and 40% of patients enrolled in group C; congenital abnormalities arose in 3.6% of group A cases and 7.1% of group B cases. No significant differences were found between the three groups in overall pregnancy outcome.
CONCLUSIONS: The results obtained from this cohort indicate that thiopurine use during pregnancy is not associated with increased risks, including congenital abnormalities.
Authors:
Jessica Coelho; Laurent Beaugerie; Jean Frédéric Colombel; Xavier Hébuterne; Eric Lerebours; Marc Lémann; Philippe Baumer; Jacques Cosnes; Arnaud Bourreille; Jean Pierre Gendre; Philippe Seksik; Antoine Blain; Etienne H Metman; Andrée Nisard; Guillaume Cadiot; Michel Veyrac; Benoît Coffin; Xavier Dray; Fabrice Carrat; Philippe Marteau;
Related Documents :
15123057 - The management of early pregnancy complications.
22909357 - Pruritic urticarial papules and plaques of pregnancy: epidemiological, clinical, and hi...
18786287 - Amniocentesis for pprom management: a feasibility study.
1641807 - Diagnosis of abnormalities of the human fetus during the first, second, and third trime...
23862557 - An analysis of the impact of embryo transfer difficulty on live birth rates, using a st...
1735477 - In vitro fertilization in unstimulated cycles: the university of southern california ex...
Publication Detail:
Type:  Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't     Date:  2010-11-29
Journal Detail:
Title:  Gut     Volume:  60     ISSN:  1468-3288     ISO Abbreviation:  Gut     Publication Date:  2011 Feb 
Date Detail:
Created Date:  2011-01-05     Completed Date:  2011-02-03     Revised Date:  2012-03-30    
Medline Journal Info:
Nlm Unique ID:  2985108R     Medline TA:  Gut     Country:  England    
Other Details:
Languages:  eng     Pagination:  198-203     Citation Subset:  AIM; IM    
Affiliation:
Department of Digestive Diseases, Lariboisière Hospital, Paris, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
6-Mercaptopurine / adverse effects*,  therapeutic use
Abnormalities, Drug-Induced / epidemiology,  etiology
Adult
Birth Weight
Cohort Studies
Female
France / epidemiology
Humans
Immunosuppressive Agents / adverse effects*,  therapeutic use
Infant, Newborn
Inflammatory Bowel Diseases / drug therapy*,  epidemiology
Maternal-Fetal Exchange
Pregnancy
Pregnancy Complications / drug therapy*,  epidemiology
Pregnancy Outcome*
Prenatal Exposure Delayed Effects
Treatment Outcome
Young Adult
Chemical
Reg. No./Substance:
0/Immunosuppressive Agents; 50-44-2/6-Mercaptopurine
Investigator
Investigator/Affiliation:
J F Colombel / ; L Beaugerie / ; P Marteau / ; X Hébuterne / ; E Lerebours / ; P Baumer / ; J Cosnes / ; M Lemann / ; A Bourreille / ; J P Gendre / ; P Seksik / ; A Blain / ; E H Metman / ; A Nisard / ; G Cadiot / ; M Veyrac / ; B Coffin / ; C Boehm / ; M Brun / ; A Cortot / ; R Fournier / ; J L Gerbal / ; M Kaassis / ; B Le Gall / ; B Mesnard / ; C Michiels / ; S Nahon / ; X Roblin / ; L Roget / ; S Schneider / ; A M Weiss / ; C Wittersheim / ; V Abitbol / ; P Afchain / ; D Barbereau / ; J Bellanger / ; P Benfredj / ; A Blanquart / ; M Blazquez / ; F Boiffin / ; P Bord / ; Y Bouhnik / ; A Charachon / ; D Chaslin-Ferbus / ; E Cuillerier / ; B David / ; Y Emery / ; O Empinet / ; P Estable / ; I Etienney / ; O Fourdan / ; D Goldfain / ; H Grimpel / ; P Houcke / ; F Jean / ; R Jian / ; G Hecquet / ; I Joly-Le-Floch / ; B Jost / ; M Lagneau / ; P Lamy / ; P Lebourgeois / ; O Leroy / ; N Mallier-Gehrke / ; P Mamou / ; D Martin / ; J F Mockly / ; X Moreau / ; B Pornin / ; P Rey / ; P Rogier / ; J Sanchez / ; J Seroka / ; J Silvie / ; D Sondag / ; R Tenenbaum /
Comments/Corrections
Comment In:
Inflamm Bowel Dis. 2012 Mar;18(3):592-3   [PMID:  21618357 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Pathogenesis of postoperative recurrence in Crohn's disease.
Next Document:  Protein tyrosine phosphatase N2 regulates TNF?-induced signalling and cytokine secretion in human in...